Compare Precigen, Inc. with Similar Stocks
Dashboard
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of -46.64% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -40.83
Negative results in Jun 25
Risky - Negative EBITDA
Stock DNA
Pharmaceuticals & Biotechnology
USD 1,331 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-0.65
-233.25%
31.79
Total Returns (Price + Dividend) 
Precigen, Inc. for the last several years.
Risk Adjusted Returns v/s 
News

Precigen, Inc. Hits Day Low of $3.88 Amid Price Pressure
Precigen, Inc. experienced notable stock volatility on November 20, 2025, with a significant decline. While the company has shown impressive annual growth, it faces financial challenges, including operating losses and a high debt-to-equity ratio, raising concerns about its long-term growth prospects amidst a fluctuating market environment.
Read full news article
Precigen Stock Opens Weak with 11.75% Gap Down Amid Market Concerns
Precigen, Inc. has opened with a notable loss, continuing a trend of significant declines over the past month. The company's market capitalization is around USD 1.265 billion, with a high return on equity but a negative price-to-book ratio. Technical indicators present mixed signals regarding its performance outlook.
Read full news article
Precigen, Inc. Hits Day Low of $4.21 Amid Price Pressure
Precigen, Inc. faced a notable stock decline today, reaching an intraday low. Despite recent gains and impressive annual returns, the company grapples with significant financial challenges, including operating losses, declining net sales, and a concerning debt situation, indicating a complex landscape in the biotechnology sector.
Read full news article Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Domestic Funds
Held in 33 Schemes (8.03%)
Held by 47 Foreign Institutions (1.67%)
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
QoQ Growth in quarter ended Jun 2025 is -30.77% vs 8.33% in Mar 2025
QoQ Growth in quarter ended Jun 2025 is 50.92% vs -175.13% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is -37.10% vs -76.95% in Dec 2023
YoY Growth in year ended Dec 2024 is -31.60% vs -20.18% in Dec 2023






